Innovative analgesic
drug candidate,

VVZ-2471

VVZ-2471

VVZ-2471

Year Target Content Results
2019 Rat Chronic pain Checking analgesic effect
2020 Rat Drug (morphine)
addiction 		Poisoning prevention and
treatment effect confirmation
2020 Rat Anxiety Confirmation of anxiety
reduction effect
2021 Mouse Depression Confirmation of depression
reduction effect

[Non-clinical Development of VVZ-2471]

On July 29, 2020, Vivozon applied for a patent for a second pipeline, VVZ-2471, and is currently conducting non-clinical toxicity studies. VVZ-2471 is a new drug candidate for treating chronic pain including neuropathic pain. Recently, the prevention and treatment potential of drug (morphine) addiction, anxiety, and depression have also been demonstrated through non-clinical studies. Upon completion of non-clinical trials for VVZ-2471, Vivozon plans to embark on clinical trials as soon as possible.

Year Target Content Results
2019 Rat Chronic pain Checking analgesic effect
2020 Rat Drug (morphine)
addiction 		Poisoning prevention and
treatment effect confirmation
2020 Rat Anxiety Confirmation of anxiety
reduction effect
2021 Mouse Depression Confirmation of depression
reduction effect

[Non-clinical Development of VVZ-2471]

Clinical Development of VVZ-2471

CT.gov = ClinicalTrials.gov

  • VVZ2471-OUD-P1-KR01

    In progress

    Phase 1

    Korea

    CT.gov
    -
    CRIS
    -

    VVZ2471-OUD-P1-KR01

    A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple- Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral VVZ-2471 in Healthy Male Volunteers